Re-assessment of the Improvement in Actual Benefit following submission of new data, on the initiative of the applicant, in accordance with Article L. 163-12 of the French Social Security Code.
-
Clinical Benefit
Substantial
The actual benefit of JEVTANA remains substantial.
Clinical Added Value
moderate
The Transparency Committee considers that JEVTANA provides a moderate IAB (level III) and is an alternative to ZYTIGA in the treatment of hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Listen
